MK2206, a selective AKT inhibitor, modulates ovarian cancer cell line sensitivity to carboplatin plus paclitaxel

被引：0
|
作者：
Zgheib, N. Bou [1 ]
Marchion, D. [1 ]
Xiong, Y. [1 ]
Stickles, X. [1 ]
Judson, P. [1 ]
Hakam, A. [1 ]
Bosquet, J. Gonzalez [1 ]
Wenham, R. [1 ]
Apte, S. [1 ]
Lancaster, J. [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [1] Chemosensitivity of a novel Akt inhibitor, MK2206, in gastric cancer cell lines
    Kim, Hyosong
    Kim, Tae Soo
    Kwan, Bo Ram
    Kim, Jeong Min
    Park, Chan Hee Park
    Jeung, Hei-Cheul
    Ahn, Joong-Bae
    Shin, Sang-Joon
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2011, 71
  • [2] Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines
    Ma, Brigette B.
    Lui, Vivian W. Y.
    Hui, Connie
    Lau, Cecilia
    Ng, Margaret
    Tsao, S. W.
    Hui, Edwin P.
    Wong, C. H.
    Yan, Li
    Chan, Anthony T. C.
    CANCER RESEARCH, 2012, 72
  • [3] Preclinical modeling of the AKT inhibitor MK2206 and topotecan in small cell lung cancer (SCLC)
    Holland, William S.
    Chinn, Danielle C.
    Lara, Primo
    Gandara, David R.
    Mack, Philip C.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
    Stottrup, Casey
    Tsang, Tiffany
    Chin, Y. Rebecca
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1964 - 1974
  • [5] The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells
    Ying-Hsi Lin
    Bert Yu-Hung Chen
    Wei-Ting Lai
    Shao-Fu Wu
    Jih-Hwa Guh
    Ann-Lii Cheng
    Lih-Ching Hsu
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388 : 19 - 31
  • [6] The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells
    Lin, Ying-Hsi
    Chen, Bert Yu-Hung
    Lai, Wei-Ting
    Wu, Shao-Fu
    Guh, Jih-Hwa
    Cheng, Ann-Lii
    Hsu, Lih-Ching
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 (01) : 19 - 31
  • [7] MK2206, an orally active allosteric AKT inhibitor, reverses progestin resistance in endometrial cancer
    Pant, A.
    Lee, I.
    Lurain, J.
    Schink, J.
    Kim, J.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 438 - 439
  • [8] MK2206, an AKT-inhibitor, sensitizes osteosarcoma cell lines to topoisomerase II inhibitors
    Galembikova, A.
    Bikinieva, F.
    Boichuk, S.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 : 142 - 142
  • [9] MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines
    Almhanna, Khaldoun
    Cubitt, Christopher L.
    Zhang, Shumin
    Kazim, Sabiha
    Husain, Kazim
    Sullivan, Daniel
    Sebti, Said
    Malafa, Mokenge
    CANCER BIOLOGY & THERAPY, 2013, 14 (10) : 932 - 936
  • [10] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    L Rhoda Molife
    Li Yan
    Joanna Vitfell-Rasmussen
    Adriane M Zernhelt
    Daniel M Sullivan
    Philippe A Cassier
    Eric Chen
    Andrea Biondo
    Ernestina Tetteh
    Lillian L Siu
    Amita Patnaik
    Kyriakos P Papadopoulos
    Johann S de Bono
    Anthony W Tolcher
    Susan Minton
    Journal of Hematology & Oncology, 7
12345